PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis

Gonzales, Emmanuel; Sturm, Ekkehard; Stormon, Michael; Sokal, Etienne; Hardikar, Winita; Lacaille, Florence; Gliwicz, Dorota; Hierro, Loreto; Jaecklin, Thomas; Gu, Joan; Desai, Nirav K.; Dorenbaum, Alejandro; Kennedy, Ciara; Baker, Alastair; Jacquemin, Emmanuel

doi:10.1016/s0618-8278(19)30211-7

PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis

Gonzales, Emmanuel

;

Sturm, Ekkehard

;

Stormon, Michael

;

Sokal, Etienne

;

Jacquemin, Emmanuel

;et.al.

(2019) The International Liver Congress (EASL) — Location: Vienne, Autriche (11.April.2019)

Files

easlGonzales.png

Open Access
PNG
82.42 KB

Download

Details

Authors

Gonzales, Emmanuel
Author
Sturm, Ekkehard
Author
Stormon, Michael
Author
Sokal, EtienneUCLouvain
Author
Jacquemin, Emmanuel
Author

Affiliations

Citations

APA
Chicago
FWB

Gonzales, E., Sturm, E., Stormon, M., Sokal, E., Hardikar, W., Lacaille, F., Gliwicz, D., Hierro, L., Jaecklin, T., Gu, J., Desai, N. K., Dorenbaum, A., Kennedy, C., Baker, A., & Jacquemin, E. (2019). PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis. Journal of Hepatology. Supplement, 70(1), e119-e120. https://doi.org/10.1016/s0618-8278(19)30211-7 (Original work published 2019)